BioCurex Enters Collaboration Agreement With Largest Cancer Research Center in Russia

11-Dec-2006

BioCurex Inc. announced that it has signed a collaboration agreement with the Blokhin Cancer Research Center in Moscow, Russia, for further development and evaluation of its RECAF(TM) technology. This new phase of the BioCurex/Blokhin collaboration is centered on the use of the RECAF marker for cancer screening, diagnosis and follow-up of treated patients using serum samples.

The Center comprises 4 separate Institutes, including a 1,600 bed hospital devoted to cancer patients. It is one of the largest in Europe employing 700 scientists and 2,000 medical personnel.

Dr. Moro, CEO of BioCurex stated: 'This collaboration is very welcome because we shall have direct access to patients, to their final diagnosis, biopsies, and serum in a comprehensive way. The access to hundreds of well documented samples, as well as the opportunity to do prospective studies is extremely important. It will allow us to characterize and adjust the assays to the practical needs in the laboratory routine, as well as gather data to present to regulatory agencies. We can assert the usefulness of RECAF in the natural environment of the clinical laboratory within a cancer center.'

The Blokhin Cancer Research Center is part of the American-Russian Cancer Alliance, which also includes the University of Maryland Greenebaum Cancer Center in Baltimore, Maryland, the Kurchatov Institute and the Fox Chase Cancer Center in Philadelphia, Pennsylvania. The US National Cancer Institute (NCI) provides the infrastructure for the Alliance.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances